CalciMedica Q3 results: AKI trial ongoing, FDA talks positive, cash to fund ops till H2 2026.

• CalciMedica reports Q3 2025 financial results • Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in AKI with respiratory failure • Data expected in 1H 2026 • Positive discussions with FDA on pivotal trial in AP; final design expected in 1H 2026 • Cash position expected to fund operations into 2H 2026